We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Abcam Merck Collaboration Produces New PD-L1 Antibody for Immuno-Oncology Research

Product News   Jul 03, 2018

 
Abcam Merck Collaboration Produces New PD-L1 Antibody for Immuno-Oncology Research

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD-L1 antibody

FURTHER INFORMATION
 
 
 

Related Product News

Adaptate Biotherapeutics Formed To Develop T-cell Modulating Antibody-based Therapies

Product News

A new company aims to modulate γd T-cell activity using therapeutic antibodies, with the potential to trigger an immune response against cancer.

READ MORE

Promising Efficacy and Toxicity Data For New Antibody Drug Conjugate

Product News

Femtogenix has announced data verifying the favorable toxicity profile and potent efficacy of its Pyridinobenzodiazepine (PDD) antibody-drug conjugate payload platform in tumor cell models.

READ MORE

Developing Potent Affimer-drug Conjugates

Product News

Avacta and ADC Therapeutics are collaborating to produce Affimer-drug conjugates for patients suffering from hematological malignancies and solid tumors.

READ MORE

Like what you just read? You can find similar content on the communities below.

Cancer Research Drug Discovery Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE